Plasma thiobarbituric acid reactive substances predicts survival in chemotherapy naïve patients with metastatic urothelial carcinoma.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
04
07
2020
revised:
10
09
2020
accepted:
10
09
2020
pubmed:
16
10
2020
medline:
16
10
2020
entrez:
15
10
2020
Statut:
ppublish
Résumé
Oxidative stress plays a significant role in development and progression of cancer, including urothelial carcinomas. TBARS (Thiobarbituric acid reactive substances) represents a marker of oxidative stress increased in various diseases. In this prospective study, we tested the hypothesis of plasma TBARS concentration and correlation with survival in chemotherapy naïve MUC (metastatic urothelial carcinoma) patients. Most of subjects (N = 65) were treated with gemcitabine and cisplatin (GC) chemotherapy. Performance status ECOG ≥2 had 11 patients, visceral metastases were present in 43. Based upon the mean of plasma TBARS, subjects were dichotomized into low and high groups. Progression-free survival (PFS), overall survival (OS) and their 95% CI were estimated by Kaplan-Meier method and compared by log-rank test. At median follow-up of 9.6 months, 65 patients experienced progression and 64 died. Subjects with low TBARS had significantly better PFS (HR 0.51) and OS (HR 0.44) opposed to high TBARS. Patients with low TBARS had significantly higher rate of neutropenia G4 and less liver involvement. High TBARS correlated with BMI above 30 kg/m
Identifiants
pubmed: 33059122
pii: S1936-5233(20)30382-X
doi: 10.1016/j.tranon.2020.100890
pmc: PMC7566937
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100890Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Pathol Oncol Res. 2020 Apr;26(2):821-831
pubmed: 30828780
Oncogene. 2006 Aug 7;25(34):4647-62
pubmed: 16892079
Int J Mol Sci. 2019 May 01;20(9):
pubmed: 31052427
Pak J Med Sci. 2016 Mar-Apr;32(2):309-13
pubmed: 27182229
Ann Oncol. 2014 Sep;25 Suppl 3:iii40-8
pubmed: 25096609
J Biol Chem. 2000 Apr 7;275(14):10527-31
pubmed: 10744745
Int J Cancer. 2016 Apr 15;138(8):1936-46
pubmed: 26566853
Lipids. 1989 Feb;24(2):125-31
pubmed: 2547130
Free Radic Biol Med. 2010 Dec 1;49(11):1603-16
pubmed: 20840865
Oxid Med Cell Longev. 2018 May 24;2018:6135739
pubmed: 29977457
Environ Health. 2012 Jun 28;11 Suppl 1:S11
pubmed: 22759493
Sci Rep. 2018 Jan 18;8(1):1129
pubmed: 29348548
Oxid Med Cell Longev. 2019 May 5;2019:2730896
pubmed: 31191796
Am J Transl Res. 2014 Nov 22;6(6):649-63
pubmed: 25628777
J Clin Oncol. 1999 Oct;17(10):3173-81
pubmed: 10506615
FEBS Lett. 1995 Jan 16;358(1):1-3
pubmed: 7821417
QJM. 2004 Dec;97(12):809-16
pubmed: 15569813
Annu Rev Pharmacol Toxicol. 2004;44:239-67
pubmed: 14744246
ISRN Oncol. 2012;2012:137289
pubmed: 23119185
Cancer Manag Res. 2017 Nov 14;9:611-626
pubmed: 29180897